Physician profile
Patrick B Mcdonough
NPI 1770791832
$1,864.48
in general payments reported to CMS, 2019-2025
19 companies · $13.50 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,386 · 2020: $365 · 2022: $99.95 · 2025: $13.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $379.51 | 2019-2020 | |
| Abbvie INC. | $242.02 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $230.97 | 2019-2020 | |
| Allergan, INC. | $160.72 | 2019 | |
| Janssen Biotech, INC. | $115.74 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $110.44 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $88.49 | 2019-2020 | |
| Gilead Sciences, INC. | $86.51 | 2019-2020 | |
| Pfizer INC. | $82.31 | 2019-2020 | |
| Ucb, INC. | $81.59 | 2019 | |
| Qol Medical, LLC | $56.60 | 2019 | |
| Ferring Pharmaceuticals INC. | $55.74 | 2019 | |
| Intercept Pharmaceuticals, INC. | $53.92 | 2019-2020 | |
| Braintree Laboratories, INC. | $27.68 | 2019-2020 | |
| Concordia Pharmaceuticals INC. | $26.73 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $25.49 | 2019 | |
| Amgen INC. | $14.10 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $13.50 | 2025 | Dupixent |
| Shire North American Group INC | $12.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Mcdonough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.